Results 31 to 40 of about 7,348 (201)

Proteomic profile of human colon organoids: effects of a multi-mineral intervention alone and in the presence of pro-inflammatory and anti-inflammatory treatments

open access: yesFrontiers in Gastroenterology
IntroductionAquamin, a multi-mineral product derived from fossilized red marine algae, has been shown to improve colon barrier structure and function.
Muhammad Nadeem Aslam   +5 more
doaj   +1 more source

Engineered Probiotics: The Next‐Generation Therapeutics to Combat Antibiotic‐Resistant Bacterial Infections

open access: yesFood Frontiers, EarlyView.
Engineered probiotics secretes fusion proteins which potentially neutralized the toxins secreted by other microbial communities. ABSTRACT On a global scale, the escalating burden of infectious diseases, predominantly attributed to bacterial pathogens, especially drug‐resistant strains, has progressed into a critical concern for clinical management and ...
Indu Singh   +11 more
wiley   +1 more source

One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer

open access: yesBulletin of the National Research Centre, 2022
Background Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world.
Dayanand Swami   +4 more
doaj   +1 more source

A case of autoimmune hepatitis in a patient with inflammatory bowel disease and significant lymphadenopathy in the porta hepatis

open access: yesJPGN Reports, EarlyView.
Abstract The diagnosis of autoimmune hepatitis (AIH) is supported by the presence of elevated transaminases, hypergammaglobulinemia, liver biopsy consistent with AIH, and the presence of AIH autoantibodies. In this case presentation, we highlight the challenges associated with diagnosing AIH in a patient with inflammatory bowel disease (IBD) who ...
Benjamin J. Malamet   +5 more
wiley   +1 more source

The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

open access: yesPLoS ONE, 2014
UnlabelledThe anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and ...
Ma Somsouk   +15 more
doaj   +1 more source

Impact of timing on mucosal healing during restaging endoscopy in pediatric Crohn's disease: A retrospective cohort study

open access: yesJPGN Reports, EarlyView.
Abstract While endoscopic remission is an important target in pediatric Crohn's disease (CD), no consensus for restaging timing exists. This retrospective cohort study assessed the timing and impact of restaging endoscopy in children with new CD in remission, comparing earlier ( ≤ 9 months) versus later endoscopy.
Anna Janecek   +7 more
wiley   +1 more source

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Ulcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy.
Shinya Nakatani   +9 more
wiley   +1 more source

Efficacy and Tolerance of 5-Aminosalicylic Acid Suppositories in the Treatment of Ulcerative Proctitis: A Review of Two Double-Blind, Placebo Controlled Trials

open access: yesCanadian Journal of Gastroenterology, 1990
The efficacy and tolerance of 500 mg 5-aminosalicylic acid (mesalamine) suppositories in the treatment of ulcerative proctitis were assessed in two double-blind, placebo controlled studies of six weeks' duration, involving a total of 173 patients.
CN Williams
doaj   +1 more source

Differential diagnosis problem of pulmonary changes in ulcerative colitis [PDF]

open access: yesVojnosanitetski Pregled, 2010
Introduction. Inflammatory intestinal diseases are often accompanied with extraintestinal and even pulmonary manifestations. The treatment of these intestinal diseases includes sulphasalazine and mesalazine, which may have undesirable allergic and other ...
Đurić Mirna   +3 more
doaj   +1 more source

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

open access: yesClinical Pharmacology: Advances and Applications, 2019
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj  

Home - About - Disclaimer - Privacy